Antitumor agent-50

Antitumor agent-50 (compound 1a) is a thiazolidinone. Antitumor agent-50 is an effective antitumor agent that has the potential for the research of osteosarcoma (OS) [1].

Antitumor agent-68 is a potent tubulin inhibitor exhibiting significant antitumor activity, with IC 50 values of 3.6 μM for HeLa and 3.8 μM for MCF-7 cells. It also demonstrates good scavenging activity of ROS and DPPH radicals in a dose-dependent manner [1].

Antitumor agent-43 (Compound 4B) is a potent antitumor compound that induces cell cycle arrest at the G2 M phase, with an IC₅₀ of 0.5 μM for T-24 cells [1].

Loxoprofen sodium dihydrate is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. It exhibits antitumor activity and can reduce atherosclerosis. This compound is a nonselective inhibitor of COX with IC50 values of 6.5 μM for COX-1 and 13.5 μM for COX-2 [1] [2] [3] [4].

Antitumor agent-70 (compound 8b) is a highly potent multi-targeted kinase inhibitor, particularly targeting c-Kit. It demonstrates remarkable anti-tumor activity and induces cell apoptosis, with strong inhibition of multiple myeloma at an IC50 value of 0.12 μM. Therefore, Antitumor agent-70 holds great potential as an effective therapy for combating cancer, especially in cases involving c-Kit. [1]

Antiproliferative agent-6 (compound 8a) is a potent antitumor compound exhibiting antiproliferative activity. It inhibits cancer cell lines HCT116, MCF-7, H460, and non-tumor aneuploid immortal keratinocyte HaCaT cells with GI50 values of 0.5 μM, 2 μM, 0.7 μM, and 3.5 μM, respectively.

Arsthinol is an antiprotozoal agent which may have anti-cancer activity. It was found that arsthinol, a trivalent organoarsenic compound (dithiarsolane), has been active in vitro on leukemia cell lines and offers a better therapeutic index than arsenic trioxide, as estimated by the ratio LD50 IC50. Arsthinol induced growth inhibition of NB4 cells at lower concentration (IC50 (concentration inhibiting growth by 50%) = 0.78 + - 0.08 micromol l after 24 h) than As(2)O(3) (IC50 = 1.60 + - 0.23 micromol l after 24 h) or melarsoprol (IC50 = 1.44 + - 0.08 micromol l after 24 h). Arsthinol-cyclodextrin complex demonstrated to have was more effective than arsenic trioxide (As2O3) and melarsoprol on the U87 MG cell line. Importantly, in the in vivo study, significant antitumor activity against heterotopic xenografts was observed after i.p. administration.

Antitumor agent-46 is an anti-tumor agent. Antitumor agent-46 demonstrates markedly higher antiproliferative activity on MCF-7 cells with an IC 50 value of 2.08 µM .

Antitumor agent-47 is a silibinin derivative with an antitumor activity. Antitumor agent-47 shows cytotoxic activity against NCI-H1299 and HT29 cells with IC 50 values of 8.07 µM and 6.27 µM, respectively .

Antitumor agent-48 is a 2,3-dehydrosilybin derivative with an antitumor activity. Antitumor agent-48 shows cytotoxic activity against MCF-7, NCI-H1299, HepG2 and HT29 cells with IC 50 values of 8.06 µM, 13.1 µM, 16.51 µM and 12.44 µM, respectively .

Antitumor agent-86 (compound 5a) demonstrates efficacy against MCF-7 breast cancer cells with an inhibitory concentration (IC 50) of 2.62 µM, promoting apoptosis and cell cycle arrest by disrupting the RAS PI3K Akt JNK signaling pathways [1].

Vanicoside E is an antioxidant and antitumor agent that inhibits L-Tyrosine and L-DOPA with IC50 values of 45.23 μM and 189.96 μM, respectively [1] [2].

Antitumor agent-120 (compound 1), a flavonoid derived from Kudzu root, exhibits negligible inhibitory effects on LNCaP and PC3 cancer cells, with IC50 values exceeding 50 μM [1].

Antitumor agent-107 (compound 5h) is an anticancer agent exhibiting potent inhibitory activity against leukemia cell lines (GI50 = 0.32-1.34 μM) and demonstrating broad-spectrum antitumor effects across various human cancer cell lines (GI50 = 0.35-9.43 μM) [1].

Antitumor Agent-122 (Compound 5j), characterized by its effective antitumor properties and minimal toxicity and resistance, exhibits strong antiproliferative effects against various cancer cell lines, including MGC-803, HepG2, SKOV3, and T24. It demonstrates IC 50 values of 5.23 μM, 3.60 μM, 1.43 μM, and 3.03 μM, respectively [1].

Antitumor agent-138 (compound 5b), with an IC 50 of 1.87 μM, inhibits tubulin polymerization at the tubulin colchicine-binding sites. It arrests the cell cycle at the G2 M phase and induces apoptosis in MCF-7 cells. Additionally, this compound suppresses cell migration and angiogenesis [1].

Antitumor agent-144 (16) functions as an anticancer compound, exhibiting IC 50 values of 2.6 μM in L1210 cells and 8.4 μM in KB cells, respectively [1].

MC-Gly-Gly-Phe-Gly-GABA-Exatecan, functioning both as an ADC linker agent and a topoisomerase inhibitor (Exatecan), displays cytotoxic and antitumor properties in vitro and in vivo [1] [2]. It specifically targets various antibodies and boasts an IC 50 of 22 μM.

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active, and ATP-competitive inhibitor of Flk-1 KDR, PDGFRβ, and FGFR1, with IC50 values of 2.1, 0.008, and 1.2 μM, respectively. (Z)-Orantinib is an effective antiangiogenic and antitumor agent that induces established tumor regression [1] [2].